Benlysta Rejected for Funding in Britain
Wednesday, July 24, 2013
Britain’s National Institute for Health and Care Excellence (NICE) rejected funding for Benlysta, the first new treatment for the condition in half a century, after reconsidering its earlier decision per an appeal by the manufacturer GlaxoSmithKline. NICE recommends which drugs should be funded by Britain's state health service.
On the go?
Text INFO to 50555 and opt-in to receive breaking news about lupus on your mobile phone.
Message and Data Rates May Apply. Text STOP to 50555 to STOP. Text HELP to 50555 for HELP. Full Terms